An open-label comparative bioavailability ( randomized crossover ) study compared a novel twice-daily minitab sprinkle formulation ( 40 mg/10 mg , Cipla Pharmaceuticals ) versus innovator syrup in HIV-infected Ugandan infants aged 3 to < 12 months ( cohort A ) and children aged 1-4 years ( cohort B ) and versus Cipla tablets ( 100/25 mg ) in children aged 4 to < 13 years ( cohort C ) .